Insights & news

European Commission Publishes Roadmap Towards Pharmaceutical Strategy for Europe

  • 03/06/2020
  • Articles

The European Commission (the Commission) published on 2 June 2020 its roadmap towards a Pharmaceutical Strategy for Europe (PSE) which it plans to publish in the fourth quarter of 2020 (see, attachment). The roadmap defines the steps which the Commission will take prior to adopting the PSE and the data which it will assemble to inform its PSE. While the Commission will consult a range of stakeholders, it has already announced a public consultation which will run until 7 July 2020.
 
The challenges which the Commission intends to tackle through the PSE include (i) the unequal access to medicines; (ii) medicine shortages; (iii) the occasional mismatch between innovation efforts and public health needs; (iv) the periodic inability to convert the fruits of European pharmaceutical research in commercial success; (v) regulatory barriers to innovation connected with genetic research, personalised therapies, smart health applications and artificial intelligence; and (vi) environmental risks associated with the production, use and disposal of medicines.
 
The Commission will pursue both non-legislative and legislative avenues and the latter may include changes to existing rules in areas such as orphan medicines and pediatric applications. The Commission also expressly wishes to take on board lessons learned from the COVID-19 pandemic with regard to crisis-preparedness and functioning supply chains.
 
The public consultation will be opened here.   

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 13/07/2020
    • Articles

    Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

    The pharmaceutical sector continues to draw competition scrutiny across Europe. United Kingdom On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.

    Read more
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *